

creon micro (Creon®)

(No. 141/04)

Solvay Healthcare
Product Update

13 December 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

New formulation for infants

Creon micro[®] granule formulation is accepted for restricted use in NHS Scotland for the treatment of pancreatic exocrine insufficiency. It provides a formulation suitable for use in young infants and is expected to be used for young cystic fibrosis sufferers who are unable to swallow capsules. The associated resource implications are expected to be small.

Chairman,
Scottish Medicines Consortium